Sands Capital: 20 Biogen transactions (Sands Capital Management LLC /

20 Sands Capital Biogen Trades

Sands Capital started to build up the position in Biogen in Q2 2013 and continued to invest until Q1 2015. Since then they sold 5.01 Million shares. The investor completely sold their stake between Q2 2015 and Q1 2018.

Avg closing price

Price range

Sold -1.14 Million shares Q1 2018

Avg closing price $310.41

Price range $260.13 - $367.91

Sold 5.7% shares (-68.4 Thousand shares) Q4 2017

Avg closing price $320.80

Price range $307.64 - $344.58

Sold 5.6% shares (-71 Thousand shares) Q3 2017

Avg closing price $296.11

Price range $271.76 - $329.69

Sold 48.4% shares (-1.2 Million shares) Q2 2017

Avg closing price $264.42

Price range $246.54 - $286.89

Sold 4.0% shares (-103 Thousand shares) Q1 2017

Avg closing price $275.09

Price range $251.52 - $297.85

Sold 7.5% shares (-210 Thousand shares) Q4 2016

Avg closing price $272.86

Price range $251.75 - $298.61

Sold 6.1% shares (-181 Thousand shares) Q3 2016

Avg closing price $272.63

Price range $222.79 - $303.87

Sold 5.4% shares (-171 Thousand shares) Q2 2016

Avg closing price $242.59

Price range $206.74 - $267.16

Sold 6.7% shares (-226 Thousand shares) Q1 2016

Avg closing price $243.15

Price range $225.62 - $273.11

Sold 18.3% shares (-754 Thousand shares) Q4 2015

Avg closing price $264.50

Price range $235.68 - $285.05

Sold 12.9% shares (-612 Thousand shares) Q3 2015

Avg closing price $303.98

Price range $250.63 - $376.94

Sold 5.5% shares (-277 Thousand shares) Q2 2015

Avg closing price $369.42

Price range $344.20 - $396.70

Increased shares by 0.7% (+35.3 Thousand shares) Q1 2015

Avg closing price $362.80

Price range $308.04 - $438.14

Increased shares by 0.4% (+22.2 Thousand shares) Q4 2014

Avg closing price $297.80

Price range $275.32 - $332.00

Increased shares by 1.2% (+60.6 Thousand shares) Q3 2014

Avg closing price $303.25

Price range $275.50 - $318.77

Increased shares by 0.4% (+18.4 Thousand shares) Q2 2014

Avg closing price $277.05

Price range $252.22 - $294.68

Increased shares by 2.5% (+119 Thousand shares) Q1 2014

Avg closing price $292.20

Price range $251.77 - $323.96

Increased shares by 2.6% (+119 Thousand shares) Q4 2013

Avg closing price $238.13

Price range $206.05 - $272.36

Increased shares by 1.5% (+69.3 Thousand shares) Q3 2013

Avg closing price $205.92

Price range $190.11 - $228.40

New holding (+4.57 Million shares) Q2 2013

Avg closing price $196.70

Price range $177.44 - $221.71

News about Biogen Inc and Sands Capital

Should You Be Confident in Biogen (BIIB)?

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of ...

Insider Monkey, about 1 year ago

RBC Capital sees Biogen stock undervaluing Leqembi prospects

RBC Capital said in a note that it sees Biogen''s stock as undervaluing the long-term prospects of its newly approved Alzheimer''s drug Leqembi. Read more here.

Seeking Alpha, over 1 year ago

Dupont Capital Management Corp Decreases Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Dupont Capital Management Corp reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 7.0% during the 4th quarter, according to its most re...

The AM Reporter, about 2 years ago